AEZS.TO Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 17:05):

Stats
Объем за сегодня	603.00
Средний объем	1 890.00
Рыночная капитализация	12.87M
EPS	$0 ( 2024-03-27 )
Дата следующего отчета о доходах	( $-1.110 ) 2024-05-06
Last Dividend	$0.0825 ( 1999-08-11 )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0 (0.00%)

AETERNA ZENTARIS INC Корреляция

10 Самые положительные корреляции
HZM.TO	0.971
IGM.TO	0.958
BRE.TO	0.958
SOLG.TO	0.957
D-UN.TO	0.956
SGR-UN.TO	0.956
CVD.TO	0.954
AP-UN.TO	0.95
TRZ.TO	0.949
MPCT-UN.TO	0.949

10 Самые отрицательные корреляции
QBTL.TO	-0.93
SBB.TO	-0.919
SNC.TO	-0.915
IAF-PI.TO	-0.915
SFC.TO	-0.902
E.TO	-0.895
PEY.TO	-0.894
RQK.TO	-0.889
U-UN.TO	-0.878
VLE.TO	-0.865

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

AETERNA ZENTARIS INC Финансовые показатели

Annual	2023
Выручка:	$4.50M
Валовая прибыль:	$4.28M (95.06 %)
EPS:	$-3.41

FY	2023
Выручка:	$4.50M
Валовая прибыль:	$4.28M (95.06 %)
EPS:	$-3.41

FY	2022
Выручка:	$5.64M
Валовая прибыль:	$5.48M (97.22 %)
EPS:	$-6.22

FY	2021
Выручка:	$5.26M
Валовая прибыль:	$5.17M (98.29 %)
EPS:	$-1.820

Financial Reports:

No articles found.

AETERNA ZENTARIS INC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

AETERNA ZENTARIS INC Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0825	1999-08-11
Last Dividend	$0.0825	1999-08-11
Next Dividend	$0	N/A
Payout Date	2007-01-02
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0825	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-28)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
1999	$0	0.00%
2000	$0	0.00%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for TSX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
XIN.TO	Dividend Knight	2023-06-26	Semi-Annually	19	1.35%
PXT.TO	Dividend King	2023-09-14	Quarterly	4	2.82%
FLRM.TO	Dividend Junior	2023-06-19	Quarterly	7	1.86%
VA.TO	Dividend Junior	2023-06-30	Quarterly	11	1.32%
MKP.TO	Dividend King	2023-09-14	Quarterly	29	6.09%
CXF.TO	Dividend King	2023-09-22	Monthly	13	2.92%
XSUS.TO	Dividend Junior	2023-09-25	Quarterly	6	0.64%
RQK.TO	Dividend Knight	2023-08-23	Monthly	8	1.42%
GWO-PN.TO	Dividend King	2023-08-30	Quarterly	14	1.89%
BDI.TO	Dividend Knight	2023-09-28	Annually	17	0.76%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-3.70	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.450	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.636	1.500	-8.18	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.57	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.49	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00754	-1.500	9.87	-10.00	[0 - 0.6]
interestCoverageTTM	-375.17	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.52	2.00	-1.175	-2.35	[0 - 30]
freeCashFlowPerShareTTM	-3.53	2.00	-1.764	-3.53	[0 - 20]
debtEquityRatioTTM	0.0153	-1.500	9.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.951	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-4.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-61.35	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.122	0.800	-2.52	-2.02	[0.5 - 2]
Total Score				-1.290

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.565	1.000	-0.158	0	[1 - 100]
returnOnEquityTTM	-0.636	2.50	-5.26	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-3.53	2.00	-1.176	-3.53	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.52	2.00	-1.175	-2.35	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0408	1.500	-3.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.81	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.95

AETERNA ZENTARIS INC

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.